These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39301135)

  • 1. Impact of bedaquiline resistance probability on treatment decision for rifampicin-resistant TB.
    Trang TPH; Kessels R; Decroo T; Van Rie A
    IJTLD Open; 2024 Sep; 1(9):384-390. PubMed ID: 39301135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
    Tu PHT; Anlay DZ; Dippenaar A; Conceição EC; Loos J; Van Rie A
    BMC Infect Dis; 2022 Nov; 22(1):876. PubMed ID: 36418994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant
    Tong E; Zhou Y; Liu Z; Zhu Y; Zhang M; Wu K; Pan J; Jiang J
    Infect Drug Resist; 2023; 16():6951-6963. PubMed ID: 37928607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam.
    Nguyen TMP; Nguyen BH; Hoang TTT; Nguyen HA; Vu DH; Nguyen MH; Nguyen BN; Decroo T; Nguyen VN
    Front Pharmacol; 2022; 13():1023704. PubMed ID: 36313324
    [No Abstract]   [Full Text] [Related]  

  • 10. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
    Trevisi L; Hernán MA; Mitnick CD; Khan U; Seung KJ; Rich ML; Bastard M; Huerga H; Melikyan N; Atwood SA; Avaliani Z; Llanos F; Manzur-Ul-Alam M; Zarli K; Binegdie AB; Adnan S; Melikyan A; Gelin A; Isani AK; Vetushko D; Daugarina Z; Nkundanyirazo P; Putri FA; Vilbrun C; Khan M; Hewison C; Khan PY; Franke MF
    Am J Respir Crit Care Med; 2023 Jun; 207(11):1525-1532. PubMed ID: 36802336
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt.
    Afifi M; Amin W; Helal D; Ashmawy R; El-Maradny YA; Khalifa N; Ghazy RM
    Sci Rep; 2024 Jul; 14(1):16247. PubMed ID: 39009633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan.
    Wu SH; Chan HH; Hsiao HC; Jou R
    Front Microbiol; 2021; 12():754249. PubMed ID: 34745058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians.
    Cesilia C; Tirtosudiro MA; Nataprawira HM
    IDCases; 2023; 34():e01880. PubMed ID: 37736021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.
    Saeed DK; Shakoor S; Razzak SA; Hasan Z; Sabzwari SF; Azizullah Z; Kanji A; Nasir A; Shafiq S; Ghanchi NK; Hasan R
    BMC Microbiol; 2022 Feb; 22(1):62. PubMed ID: 35209842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.